Breaking News, Collaborations & Alliances

Biostax, Immgenuity Ink Agreement to Pursue Remission in HIV

Aims to advance the development of novel immunotherapies for the treatment of HIV and other diseases.

Immune Therapeutics, Inc., (a Biostax Corp.) a hub-and-spoke biotech development engine, signed a research collaboration agreement with Immgenuity, Inc. The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal and JKB-122 to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achieve remission with HIV patients. Immgenuity and Biostax will collaborate to advance the development of novel immunotherapies for the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters